Sign in

You're signed outSign in or to get full access.

Destiny

Research Analyst at Ladenburg

Destiny Hance is an Associate Director of Research at Ladenburg Thalmann, serving as an equity research analyst with a focus on special purpose acquisition companies (SPACs) and related equity markets. She has participated in industry events such as The SPAC Conference, reflecting her specialization in SPAC research and capital markets. Hance began her equity research career at Ladenburg Thalmann as an intern in March 2017 and has since progressed into a senior associate-level research role at the firm. Publicly available profiles describe her as a research professional at a FINRA-member broker-dealer, though detailed performance rankings, specific stock coverage lists, and license designations are not comprehensively disclosed in open sources.

Destiny's questions to NEUROONE MEDICAL TECHNOLOGIES (NMTC) leadership

Question · Q4 2025

Destiny (on behalf of Jeff Cohen) inquired about the expected number of additional trigeminal nerve ablation procedures before year-end, the feasibility of stacking these procedures, the timeline for a strategic partnership for this technology, future orders from the large pharmaceutical company for drug delivery devices, the timing for establishing and opening the epilepsy registry, and current strategies for raising patient awareness.

Answer

Dave Rosa, CEO of NeuroOne Medical Technologies Corporation, confirmed expectations for more trigeminal nerve ablation cases this month, noting that procedures can be scheduled back-to-back. He expressed confidence in securing a strategic partner for the trigeminal nerve ablation system. Regarding drug delivery, Mr. Rosa anticipated shipping additional preclinical units around mid-year. For the epilepsy registry, he projected paperwork completion and site sign-off by Q2. Mr. Rosa also highlighted ongoing efforts to partner with organizations like CURE and the Epilepsy Foundation to enhance patient awareness, citing recent positive patient stories.

Ask follow-up questions

Fintool

Fintool can predict NEUROONE MEDICAL TECHNOLOGIES logo NMTC's earnings beat/miss a week before the call

Question · Q4 2025

Destiny (on for Jeff Cohen with Ladenburg) inquired about the expected number of OneRF trigeminal nerve ablation procedures before year-end, the feasibility of stacking these procedures, the strategy for securing a strategic partner for trigeminal nerve ablation versus independent commercialization, the potential for additional orders and expanded testing from the large pharmaceutical company for drug delivery devices, the timeline for establishing and opening the epilepsy registry, and NeuroOne's initiatives to raise patient awareness for their therapies in fiscal year 2026.

Answer

CEO Dave Rosa confirmed that three other centers have planned cases for trigeminal nerve ablation, with more expected this month, and that procedures can be done back-to-back. He expressed confidence in securing a strategic partner for this technology. Regarding drug delivery, Mr. Rosa anticipates shipping additional preclinical units around mid-year 2026. For the epilepsy registry, he expects paperwork and site sign-offs to occur in Q2 2026, following a productive meeting with participating sites in December. Mr. Rosa also highlighted ongoing efforts to partner with organizations like CURE and the Epilepsy Foundation to increase patient awareness, citing a recent success story of a professional pianist.

Ask follow-up questions

Fintool

Fintool can write a report on NEUROONE MEDICAL TECHNOLOGIES logo NMTC's next earnings in your company's style and formatting